Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL15328872 | 0.98 | MAPT (0.48) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL1000103 | 0.86 | MAPT (0.58) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL5946197 | 0.80 | MAPT (0.57) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL2498762 | 0.80 | MAPT (0.52) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL31211203 | 0.80 | MAPT (0.57) | MAPTNPSR1NQO2POLBL3MBTL1 | |
| SCHEMBL146892 | 0.78 | ALDH1A1 (0.58) | MAPTNQO2POLBGAAALOX15 | |
| SCHEMBL24722948 | 0.78 | HPGD (0.40) | MAPTPOLBL3MBTL1GAAALDH1A1 | |
| SCHEMBL30436671 | 0.77 | ACHE (0.52) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL5161298 | 0.77 | MAPT (0.43) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL30700955 | 0.77 | ALDH1A1 (0.59) | MAPTNPSR1POLBL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2026087650-A1 | VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| US-20260092073-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260092076-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695243-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694889-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | Acelot, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4630420-A1 | INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-3461809-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-1668011-A2 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006015985-A1 | HIV INHIBITING 1,2,4-TRIAZIN-6-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| EP-1597242-A1 | HIV INHIBITING 1,2,4-TRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005028479-A2 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004074266-A1 | HIV INHIBITING 1,2,4-TRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | MAPT 187/4885NPSR1 4672/4885NQO2 3655/4885 |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | MAPT 3040/4885NPSR1 2811/4885NQO2 418/4885 |
| US-20260092073-A1 | NOVEL COMPOUNDS | CBR1, CBR3, ARRB1 | MAPT 4392/4885NPSR1 818/4885NQO2 819/4885 |
| US-20260092076-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, ARRB1 | MAPT 3398/4885NPSR1 340/4885NQO2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.